Regentis Biomaterials Ltd. (RGNT) is currently trading at $3.9 with a Wall Street consensus price target of $10.0, implying potential upside of 156.4% over the next 12 months. 1 analysts currently cover RGNT, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $10.0.
RGNT operates in the Healthcare sector with a market capitalisation of $27M. The stock is down 42.1% year-to-date and is currently trading near the lower end of its 52-week range of $1.23 – $15.5.
Other Healthcare stocks with comparable size and valuation.
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →